Axogen’s DeVinney sells $18,521 in shares

Axogen, Inc. NASDAQ:AXGN Chief Innovation Officer Erick Wayne DeVinney sold 1,137 shares of common stock on September 16, 2025, at a price of $16.29, for a total value of $18,521. The transaction comes as Axogen, with a market capitalization of $770 million, trades near its InvestingPro Fair Value, while maintaining a "GOOD" financial health rating.

On September 13, 2025, DeVinney also acquired 2,500 shares of common stock at $0.00, for a total value of $0, These shares were issued upon the attainment of certain performance criteria. The sale of shares was mandated by Axogen’s election to cover tax withholding obligations related to the vesting of performance stock units.

Following these transactions, DeVinney directly owns 220,649 shares of Axogen, Inc. The company has shown strong revenue growth of 17% over the last twelve months, and InvestingPro analysis reveals 8 additional key insights about the company’s performance and outlook.

In other recent news, AxoGen, Inc. has encountered a delay in the review timeline for its Avance Nerve Graft application. The U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date by three months, setting a new target of December 5, 2025. This extension follows the FDA’s classification of AxoGen’s response to an information request as a "Major Amendment" due to substantial new manufacturing and facility data. Despite this setback, Raymond James has reiterated an Outperform rating for AxoGen, maintaining a price target of $20.00. The firm acknowledges that while the delay is not ideal, it is not entirely unexpected given the unique nature of the filing. These developments are crucial for investors monitoring the company’s progress and regulatory interactions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.